NAMS
NASDAQ HealthcareNewAmsterdam Pharma Company N.V. - Ordinary Shares
Biotechnology
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
๐ Market Data
| Price | $26.90 |
|---|---|
| Volume | 819,789 |
| Market Cap | 3.22B |
| Beta | 0.110 |
| RSI (14-Day) | 23.6 Oversold |
| 200-Day MA | $33.38 |
| 50-Day MA | $30.89 |
| 52-Week High | $42.20 |
| 52-Week Low | $23.05 |
| Forward P/E | -17.26 |
| Price / Book | 4.72 |
๐ฏ Investment Strategy Scores
NAMS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (95/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NAMS in your text
Paste any article, transcript, or post โ the tool will extract NAMS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.